» Articles » PMID: 28343357

Gut Microbiome in Chronic Kidney Disease

Overview
Date 2017 Mar 27
PMID 28343357
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

With over 100 trillion microbial cells, the gut microbiome plays important roles in both the maintenance of health and the pathogenesis of disease. Gut microbiome dysbiosis, resulted from alteration of composition and function of the gut microbiome and disruption of gut barrier function, is commonly seen in patients with chronic kidney disease (CKD). The dysbiotic gut microbiome generates excessive amounts of uremic toxins, and the impaired intestinal barrier permits translocation of these toxins into the systemic circulation. Many of these uremic toxins have been implicated in the progression of CKD and increased cardiovascular risk. Various therapeutic interventions have been proposed that aim to restore gut microbiome symbiosis. If proven effective, these interventions will have a significant impact on the management of CKD patients. In this review, we discuss the consequences of gut microbiome dysbiosis in the context of CKD, discuss the consequences of gut dysbiosis, and highlight some of the recent interventions targeting the gut microbiome for therapeutic purposes.

Citing Articles

Dietary Phosphorus Levels Influence Protein-Derived Uremic Toxin Production in Nephrectomized Male Rats.

Cladis D, Burstad K, Biruete A, Jannasch A, Cooper B, Hill Gallant K Nutrients. 2024; 16(12).

PMID: 38931160 PMC: 11207110. DOI: 10.3390/nu16121807.


Study on the mechanism of hirudin multi target delaying renal function decline in chronic kidney disease based on the "gut-kidney axis" theory.

Long C, Zhang C, Xie Y Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(10):7951-7962.

PMID: 38758227 PMC: 11450085. DOI: 10.1007/s00210-023-02888-6.


Design and rationale for an open-label, randomized, controlled pilot trial to evaluate the changes in blood uremic toxins in patients with chronic kidney disease by dietary therapy with sake lees.

Tokumaru T, Toyama T, Nakade Y, Ogura H, Oshima M, Nakagawa S Clin Exp Nephrol. 2024; 28(5):440-446.

PMID: 38340247 PMC: 11033224. DOI: 10.1007/s10157-023-02450-x.


Fortified synbiotic dessert for improving malnutrition in hemodialysis patients: A randomized, double-blind, controlled trial.

Azad F, Hamidianshirazi M, Mazloomi S, Shafiee M, Ekramzadeh M Food Sci Nutr. 2023; 11(12):8082-8092.

PMID: 38107115 PMC: 10724616. DOI: 10.1002/fsn3.3728.


Animal Models for Studying Protein-Bound Uremic Toxin Removal-A Systematic Review.

Ahmed S, Vries J, Lu J, Stuart M, Mihaila S, Vernooij R Int J Mol Sci. 2023; 24(17).

PMID: 37686004 PMC: 10487432. DOI: 10.3390/ijms241713197.


References
1.
Magnusson M, Magnusson K, Sundqvist T, DENNEBERG T . Increased intestinal permeability to differently sized polyethylene glycols in uremic rats: effects of low- and high-protein diets. Nephron. 1990; 56(3):306-11. DOI: 10.1159/000186158. View

2.
Krishnamurthy V, Wei G, Baird B, Murtaugh M, Chonchol M, Raphael K . High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int. 2011; 81(3):300-6. PMC: 4704855. DOI: 10.1038/ki.2011.355. View

3.
Wang I, Wu Y, Yang Y, Ting I, Lin C, Yen T . The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Benef Microbes. 2015; 6(4):423-30. DOI: 10.3920/BM2014.0088. View

4.
Yang T, Santisteban M, Rodriguez V, Li E, Ahmari N, Carvajal J . Gut dysbiosis is linked to hypertension. Hypertension. 2015; 65(6):1331-40. PMC: 4433416. DOI: 10.1161/HYPERTENSIONAHA.115.05315. View

5.
Takayama F, Taki K, Niwa T . Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis. 2003; 41(3 Suppl 1):S142-5. DOI: 10.1053/ajkd.2003.50104. View